TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained prior to participation in the study~* Must have an additional dose of unexpired, commercial tisagenlecleucel available and prescribed by a physician in the course of medical practice~* Age up to and including 25 years~* Patients must have CD-19+ Leukemia~* Patients who were previously treated with tisagenlecleucel and present with evidence of B-cell recovery as defined by: Peripheral blood (PB) absolute B lymphocyte count ≥ 50/µL, OR PB B lymphocyte ≥ 10% of the total lymphocytes~Exclusion Criteria:~* Prior gene therapy other than tisagenlecleucel~* Prior adoptive T cell therapy other than tisagenlecleucel~* Active CNS involvement by malignancy~* Active or latent hepatitis B or active hepatitis C, or any uncontrolled infection at screening~* HIV positive test within 8 weeks of screening

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Tisagenlecleucel (Type: EXPERIMENTAL): Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk and Benefit Informed MTM Pharmacist Intervention in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All adult Geisinger patients with heart failure, as identified by a validated EHR (Electonic Health Record)-based phenotype algorithm,~* Patients with a Geisinger primary care provider (PCP)~* Patients who follow with Geisinger Cardiology (at least 1 visit in past two years).~* Fulfills the specifications for arm assignment based on the results of the care gap benefit model.~Exclusion Criteria:~* Patients with a Geisinger PCP or Cardiologist in the South Central Region (part of the Geisinger Holy Spirit footprint) as MTM availability is limited in this service area.~* Patients who have indicated they do not wish to participate in research studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High benefit, MTM (Type: EXPERIMENTAL): This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
- High benefit, no MTM (Type: NO_INTERVENTION): This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
- Low benefit, MTM (Type: ACTIVE_COMPARATOR): This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Psychological Treatment in Psychiatric Inpatient Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older.~* Treated according to the compulsory psychiatric care act.~* Meet the criterion of informed consent.~Exclusion Criteria:~* Lack the cognitive ability to acquire the treatment intervention, such as impaired attention, memory, logic and reasoning, and also auditory and visual processing. This will be based on a clinical assessment by the ward team, including the attending psychiatrist and a clinical psychologist.~* Ongoing psychological treatment parallel to the admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Acceptance & Commitment Therapy (ACT) (Type: EXPERIMENTAL): Psyhotherapy based on principles of functional analysis, behavioral activation, and experiential avoidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Families who have had children diagnosed with any type of cancer in the past year.~* At least one sibling between the ages of 4 and 10 years old~* Patients will be targeted 1-2 months after diagnosis, but could be included in the study up to 12 months following diagnosis.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Active Control Group (Type: SHAM_COMPARATOR): Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
- Play Intervention (Type: EXPERIMENTAL): children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 50 and above, male and female starting on Pradaxa or Warfarin for nonvalvular atrial fibrillation~2. Able to ambulate independently and travel to UConn Health in Farmington CT-~Exclusion Criteria:~1. Prior known history of osteoporosis~2. Chronic kidney disease with creatinine clearance less than 30~3. Serum 25 hydroxyvitamin D level less than 10~4. Ongoing treatment with medications that interfere with bone metabolism such as steroids, bisphosonates, denosumab, estrogen, SERMS~5. Hypercalcemia, a history of Paget's disease, a history of multiple myeloma, or a history of monoclonal gammopathy of uncertain significance -

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pradaxa (Type: None): 20 men and 20 women on Pradaxa for non valvular atrial fibrillation
- Warfarin (Type: None): 20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Expiratory Muscle Strength Training and Phonation Resistance Training Exercises For Elderly Patients With Vocal Fold Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65 or older~* Diagnosis of presbyphonia (vocal fold atrophy) made by a fellowship-trained laryngologist and a voice specialized speech language pathologist~* Willingness to be randomized to one of two treatments~Exclusion Criteria:~* Any concomitant laryngeal diagnoses or diseases known to affect voice function, including: amyloidosis, arytenoid dislocation, laryngeal cancer, cricoarytenoid fixation, vocal fold cyst(s), vocal nodules, vocal fold polyp(s), dysplasia, vocal fold fibrous mass(es), glottal web, vocal fold immobility, laryngeal stenosis, laryngocele, leukoplakia, Parkinson's disease, Reinke's edema, respiratory recurrent pneumonia, sarcoidosis, spasmodic dysphonia~* Any chronic lower airway disease such as chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis, emphysema, cystic fibrosis~* History of acute stroke~* Untreated hypertension~* Untreated gastroesophageal reflux disease (GERD)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- PhoRTE (Type: ACTIVE_COMPARATOR): This group will undergo standard PhoRTE therapy.
- PhoRTE + EMST (Type: EXPERIMENTAL): This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have completed 52 weeks of treatment of the double blind placebo-controlled phase of ALS-TAL-201.~* Women must be postmenopausal, surgically sterile, or using adequate birth control methods.~* Patients must be willing and able to give written informed consent prior to performing any open-label study procedures.~Exclusion Criteria:~* Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right Bundle Branch Block~* Patients using any of the following:~  * Chronic use of lithium carbonate~ * Chronic use of mecasermin (rhIGF-1)~ * Chronic use of minocycline~ * Chronic use of more than 600mg/day coenzyme Q10~ * Chronic use of any marketed drug, if its use was not clearly indicated for any underlying medical condition other than ALS (symptomatic drugs for ALS and supplements allowed)~* Patients participating in any other investigational drug study and use of any other investigational drug~* Patients taking drugs that may interact with Talampanel~* Females who are pregnant or nursing.~* Females of child-bearing potential who do not practice medically acceptable methods of contraception.~* Any condition of the patient which the investigator feels may interfere with participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Talampanel (Type: EXPERIMENTAL): Talampanel 50mg tid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female. (If female of child bearing potential and outside of the window of 10 days since the last menstrual period, a negative serum or urine pregnancy test is required.)~* Known or suspected soft tissue sarcoma~* Age equal to or greater than 15 years~* Able and willing to follow instructions and comply with the protocol~* Provide written informed consent prior to participation in this study~* Karnofsky Performance Scale score 60-100~Exclusion Criteria:~* Nursing or pregnant females~* Age less than 15 years~* A history of malignancy other than soft-tissue sarcoma (excluding basal cell carcinoma and cervical intraepithelial neoplasia)~Recruitment: Study subjects will be referred to the Cross Cancer Oncologic Imaging Department by their physicians. The patient's study eligibility will be confirmed during the booking telephone call and eligible, interested patients will be scheduled for a PET scan.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Eligibility Criteria:~Inclusion Criteria:~* Diagnosis of histologically proven primary or metastatic cancer requiring thoracic radiation therapy OR radiation therapy to the head and neck or brain~* At least 18 years of age.~* Planning to undergo proton or photon beam radiation therapy as part of the clinical management of the diagnosed cancer.~* Able to understand and willing to sign an IRB-approved written informed consent document.~Exclusion Criteria:~* Implanted metallic objects in the region to be scanned excepting dental prostheses~* IV or oral contrast medium within 24 hours prior to DECT image acqusition~* Pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dual-Energy CT scan (Type: EXPERIMENTAL): Patients enrolling in this study will undergo additional sequential DECT scan in addition to their routine SECT or DECT scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has confirmed partial onset seizures.~* Seizure activity is not adequately controlled by patient's current AED regimen.~* Patient is between 16 and 75 years of age.~* Patient is able to give accurate seizure counts and health outcomes information. Patient is able to complete study instruments with minimal assistance.~* Patient has previously failed at least 3 AEDs in single or combination use.~* During baseline evaluation period, patient should take at least 1 AED.~* Patient should have confirmed epilepsy for a minimum of 2 years.~* Patient's AED regimen is stable for at least 1 month prior to enrolment.~* Patient has at least 1 objective partial onset seizure per month during the 2 months prior to enrolment.~* Patient or legal guardian understands study procedures and has voluntarily signed an informed consent in accordance with institutional and local regulatory policies.~Exclusion Criteria:~* Patient has pseudoseizures or a history of pseudoseizures.~* Patient has idiopathic generalised epilepsy or unclassified epilepsy.~* Patient has ever received direct brain stimulation (cerebella or thalamic) for treatment of epilepsy.~* Patient has had a unilateral or bilateral cervical vagotomy.~* Patient has a history of non-compliance with the completion of a seizure diary.~* Patient has taken an investigational drug within a period of 3 months prior to inclusion.~* Patient is currently using another investigational medical device.~* Patient has a significant cardiac or pulmonary condition currently under treatment.~* Patient has previously undergone brain surgery.~* Patient has a demand cardiac pacemaker, implantable defibrillator, or other implantable stimulator.~* Patient currently lives more than 2 hours from the study site or plans to relocate to a location more than 2 hours from the study site within one year of enrolment in the Study.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VNS Therapy (Type: EXPERIMENTAL): VNS Therapy + Best Medical Practice
- Best Medical Practice (Type: ACTIVE_COMPARATOR): Best Medical Practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~* Healthy female volunteers of non-childbearing potential~Exclusion Criteria:~* History of any clinically significant medical, neurologic, or psychiatric disease (including repeated episodes of major depression) or a disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation~* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8418

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of Crohn's disease.~2. Patients in sustained remission with PCDAI 0 \> 6 months~3. Ages 8-20~4. Normal CRP (CRP\<0.5), normal Calprotectin (\<100)~5. Patients with uncomplicated disease~6. Signed informed consent~Exclusion Criteria:~1. Patients with active disease (PCDAI \>10)~2. Pregnancy~3. Patients with complicated disease (B2, B3)~4. Patients with recent onset use of an immunomodulator \<12 weeks, or dose change in past 12 weeks.~5. Patients with current use of biologics.~6. Elevated CRP or Calprotetcin\>100 at screening.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- a milk fat or gluten challenge (Type: EXPERIMENTAL): patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Changes of Blood Pressure Between Day and Night

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients with OSA who don't meet the above mentioned exclusion criteria~Exclusion Criteria:~1. Patients who have a normal diurnal sleep pattern (i.e. decrease of more than 30% of the systolic BP at night time)~2. Patients who are on three or more antihypertensives whose blood pressure is not controlled.~3. Patients previously treated with CPAP therapy within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Compliant with CPAP
- 2 (Type: None): noncompliant with CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues